At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 40 enrolled
Drug / intervention
Jaktinib Hydrochloride Tablets +2 moredrug
Likely dose
Jaktinib Hydrochloride Tablets 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Jaktinib in Healthy Volunteers
In Brief
A Phase 1 clinical trial evaluating Jaktinib Hydrochloride Tablets, Itraconazole capsule, and 1 other intervention for Healthy Volunteers. Completed, enrolled 40 participants across 1 site.
Detailed Summary
The primary objective of this study was to assess the effect of rifampicin and itraconazole, on the pharmacokinetics (PK) of Jaktinib in healthy Volunteers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesChina
Collaborators--
Timeline
Phase 1CompletedFinished
20222023202420252026
Enrollment StartOct 2021
Primary CompletionJan 2022
First PostedFeb 2024
TodayJul 2026
First PostedFeb 7, 2024
Enrollment StartOct 27, 2021
Primary CompletionJan 12, 2022
TodayJul 1, 2026
Enrollment to primary: 3 monthsPosted 2.4 years ago
Interventions
Jaktinib Hydrochloride Tabletsdrug
Oral Jaktinib 100 mg for 1 day
Itraconazole capsuledrug
Oral Itraconazole 200 mg for 9 day
Rifampicin Capsulesdrug
Oral Rifampicin 600 mg for 11 day